as of 11-16-2026 3:45pm EST
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 1.4B | IPO Year: | 2020 |
| Target Price: | $21.79 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.72 | EPS Growth: | 19.67 |
| 52 Week Low/High: | $7.23 - $14.68 | Next Earning Date: | 11-16-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -10.47 | Index: | |
| Free Cash Flow: | -111682000.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chief Financial Officer
Avg Cost/Share
$13.53
Shares
14,000
Total Value
$189,390.60
Owned After
69,828
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$13.69
Shares
77,000
Total Value
$1,053,814.30
Owned After
69,828
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | ORIC | Chief Financial Officer | Oct 20, 2026 | Sell | $13.53 | 14,000 | $189,390.60 | 69,828 | |
| Piscitelli Dominic | ORIC | Chief Financial Officer | Aug 26, 2026 | Sell | $13.69 | 77,000 | $1,053,814.30 | 69,828 |
SEC 8-K filings with transcript text
Nov 16, 2026 · 100% conf.
1D
+6.36%
$8.01
5D
+12.13%
$8.45
20D
+19.15%
$8.98
2 oric-ex99_1.htm
Exhibit 99.1
ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collaboration and supply agreement with Bayer
Provided updated rinzimetostat combination data in post-abiraterone mCRPC and in post-AR inhibitor mCRPC, consisting of landmark rPFS estimates in both populations that remain consistent with competitor PRC2 inhibitor, and reconfirming a highly differentiated safety profile
Presented potential best-in-class enozertinib data at ESMO Congress 2026, including 84% systemic ORR and 70% CNS ORR, setting a new benchmark in 1L EGFR atypical NSCLC
Announced Redwood-1 global Phase 3 registrational trial in 1L EGFR atypical NSCLC, with initiation expected in 1H 2027
Cash and investments of approximately $345 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout from first Phase 3 trial for rinzimetostat
SOUTH SAN FRANCISCO and SAN DIEGO, CA – November 16, 2026 – ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today reported financial results and provided operational updates for the quarter ended September 30, 2026, and a rinzimetostat program update.
“Recent clinical data updates reinforce our confidence in the best-in-class potential of our late-stage portfolio, with rinzimetostat continuing to demonstrate an efficacy and safety profile in prostate cancer that is differentiated from current standards of care and the only other PRC2 inhibitor in Phase 3 development, and with enozertinib setting a new benchmark in 1L EGFR atypical NSCLC,” said Jacob M. Chacko, M.D., president and chief executive officer. “With the first Phase 3 trials either underway or planned across both programs and supported by a strong balance sheet, we are laser focused on execution in pursuit of our mission to Overcome Resistance In Cancer.”
Third Quarter 2026 and Other Recent Highlights
Rinzimetostat: a potent and selective allosteric inhibitor of PRC2
Second Half 2026 Program Update
The Company conducted a pre-planned biannual Periodic Safety Review (PSR) in October 2026 for the ongoing Phase 1b dose-optimization cohorts evaluating 400 mg QD rinzimetostat in
combination with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone and in patients with mCRPC previously treated with an androgen receptor (AR) inhibitor. As of August 14, 2026, with a median follow-up of approximately 8 months, the safety profile across both patient populations was consistent with the prior March 2026 data disclosure; the vast majority of treatment-related adverse events (TRAEs) were Grade 1 in severity and consistent with PRC2 and AR inhibition. The most common TRAEs were fatigue (32%; 11% Grade 1, 16% Grade 2, and 5% Grade 3), diarrhea (24%; 19% Grade 1 and 5% Grade 2), and nausea (22%; 19% Grade 1 and 3% Grade 2), which are similar rates and grades to the March 2026 disclosure. Consistent with the prior disclosure, there were no Grade 4 or 5 adverse events attributed to rinzimetostat or darolutamide. These data continue to demonstrate a highly differentiated safety profile, with significantly lower frequency and severity of adverse events, nearly all Grade 1 or 2, and fewer treatment modifications than competitor regimens.
In parallel with the PSR, longer-term durability was also evaluated across both patient populations.
• Post-abiraterone cohort: At the time of the previous data disclosure (March 6, 2026 data cutoff), of 18 efficacy-evaluable patients in this cohort, 7 remained on treatment without radiographic progression. As of the August 14, 2026 data cutoff, 2 of these 7 patients discontinued treatment due to radiographic progression (one at more than 13 months and one at more than 11 months), and 5 patients remained on treatment without radiographic progression, with the longest ongoing at nearly 17 months. While still preliminary with 28% of patients ongoing, landmark rPFS rates continue to demonstrate meaningful and durable clinical benefit for rinzimetostat in combination with darolutamide compared to competitor data and historical outcomes with approved therapies. With a median follow-up of 7.8 months, landmark rPFS rates of 59% at each of 8, 9, and 10 months are consistent with the competitor PRC2 inhibitor currently in multiple Phase 3 trials in prostate cancer (mevrometostat in combination with enzalutamide demonstrated estimated landmark rPFS rates of 63% at each of 8, 9, and 10 months in a post-abiraterone patient population). These rinzimetostat landmark rPFS rates are superior to reported outcomes for available standard-of-care therapies,
Aug 3, 2026 · 100% conf.
1D
+4.77%
$11.11
Act: +20.70%
5D
+10.31%
$11.69
Act: +28.49%
20D
+18.78%
$12.59
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.ed18d017.1786388492.cff43cf1
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
May 4, 2026 · 100% conf.
1D
-1.69%
$9.47
Act: -0.62%
5D
-6.23%
$9.03
Act: -6.65%
20D
-1.11%
$9.52
Act: -20.87%
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.c706d217.1784895508.2cf5c223
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
See how ORIC stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "ORIC Oric Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.